Roche (RHHBY.PK) Merger and Acquisition Call January 25, 2012, 07:00 a.m. ET Executives Severin Schwan - CEO, Roche Group Alan Hippe - Chief Financial and IT Officer Dan O'Day - Diagnostics Division, COO and Member of the Roche Corporate Executive Committee Analysts Sachin Jain - Bank of America/Merrill Lynch Gbola Amusa - UBS Bill Quirk - Piper Jaffray Quintin Lai - Robert W. Baird Vincent Meunier - Exane BNP Paribas Alexandra Hauber - JP Morgan Luisa Hector - Crédit Suisse Michael Leacock - RBS Keyur Parekh - Goldman Sachs PresentationSeverin Schwan
Welcome to everybody, and thank you for joining our call, which is going to last for about one hour. This is Severin speaking, and with me today, Alan Hippe, our Chief Financial Officer; and Dan O’Day, Chief Operating Officer of Roche Diagnostics. Illumina is a great successful company, and we are excited to share with you the background of this planned acquisition. At the beginning, just let me shortly put this transaction into context. An important element of today’s success of Roche Diagnostics is our breadth and depth of various key measuring technologies. They allow us to develop and market a broad range of diagnostic tests from molecular diagnostics to serum work area or tissue diagnostic testing. The completeness of our offering is important, both for our customers and Roche. Over the years, we have developed a number of high-tech platforms, both internally and also as you can see on Page 4, by acquiring a number of key technologies. And we believe that sequencing is and will continue to be an increasingly important technology as we go forward.